This inventor holds 3 USPTO granted patents and 4 published patent applications. Top assignee: Tolera Therapeutics, Inc.. Active years: 2013-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013-2015
Title: John J Puisis: Innovator in Immunology
Introduction
John J Puisis is a notable inventor based in Glenview, IL (US), recognized for his contributions to the field of immunology. He holds a total of 3 patents that focus on innovative methods for treating inflammatory and autoimmune diseases.
Latest Patents
His latest patents include groundbreaking work on antibodies and methods for selective inhibition of T-cell responses. These inventions provide compositions, methods, and assays aimed at treating inflammatory and autoimmune diseases, as well as preventing transplanted tissue rejection. Specifically, his work involves anti-αβ TCR antibodies, which are designed to bind to αβ TCR. The patents also detail therapeutic dosing regimens of these antibodies and methods for upregulating the numbers of regulatory T-cells (Treg) to enhance treatment efficacy.
Career Highlights
John J Puisis is currently associated with Tolera Therapeutics, Inc., where he continues to advance research in immunotherapy. His work has significant implications for patients suffering from various immune-related conditions.
Collaborations
He collaborates with esteemed colleagues, including Daniel R Getts and James J Herrmann, to further enhance the impact of his research and innovations in the field.
Conclusion
John J Puisis stands out as a significant figure in the realm of immunology, with his innovative patents paving the way for new treatments in inflammatory and autoimmune diseases. His contributions are vital for advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile